Bristol-Myers Squibb registers observational study of first-line Reblozyl in lower-risk MDSAug 7Trial updateBristol Myers Squibbluspatercept
Geron reports Q2 2026 results as RYTELO revenue climbs to $57.5 millionAug 6Quarterly updateGeron Corporationimetelstat
Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programsJul 30Quarterly updateBristol Myers Squibbluspatercept
BMS week: two label updates, new luspatercept CKD trial, pulmonary fibrosis study registeredJul 24Weekly roundup, 6 itemsadagrasibBristol Myers Squibb
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Sign inSign in